

The pharmaceutical company Dicot is gearing up for next phase

Press release: Uppsala, February 7, 2022. The pharmaceutical company Dicot strengthens its management ahead of next phase in the company's development. Current VP and COO Elin Trampe is appointed CEO and will succeed current CEO Göran Beijer from April 1, 2022. Björn Petersson takes over as new CFO from March 7, 2022.

The pharmaceutical company Dicot develops drugs within sexual dysfunctions with focus on bringing the drug candidate LIB-01 into clinical phase. Dicot will now strengthen and broaden the management team with the objective to take the company to the next phase and focus on clinical results, business development and international partnerships. Current COO (Chief Operating Officer) and VP, Elin Trampe, will take over as CEO on April 1, 2022. Elin Trampe succeeds current CEO Göran Beijer, who has been CEO of Dicot for five years. Göran Beijer will continue to be actively involved in the company's development as a consultant and will work with the CEO primarily on business development and investor relations.

Elin Trampe was recruited in 2021 to Dicot as COO and VP. Elin Trampe has previously worked in the management team of Oasmia Pharmaceutical and Jacobs Douwe Egberts SE and held leading positions and international roles in several companies incl. the global companies Mondelēz International and GE Global Operations. Elin Trampe has extensive experience in business development, strategic international partnerships, operational excellence and product development.

“Elin has very broad and valuable competences and combined with her strong drive and commitment we will together develop the company further. I am also very pleased that Göran, who has made and is making a very good contribution as CEO of Dicot, remains as a consultant. That means continuity and stability”, says Eva Sjökvist Saers, Chairman of the Board of Dicot AB.

“I am very much looking forward to take on the responsibility as CEO of Dicot and to further develop the company and its operations. Dicot's pharmaceutical candidate meets a large global medical need and has enormous market potential with a given place on the world market. I have got a flying start in the company alongside Göran and I am happy that he remains in the company”, says Elin Trampe, appointed new CEO.

Björn Petersson replaces Jessica Roxhed as CFO when Jessica moves on to other assignments. Björn Petersson has broad experience as CFO from various companies. In recent years, he has had several assignments in life science, as Karessa, Cavid and NeoDynamics. In 2021, Björn was involved in the IPO of Flat Capital on First North. Björn will take over as CFO on March 7, 2022.

The recruitment of a Chief Science Officer (CSO) to Dicot's management team is ongoing. The CSO will be responsible for the scientific development and the clinical program.

DICOT

For further information, please contact:

Göran Beijer CEO

Tel: +46 706 63 60 09

Email: goran.beijer@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.
